S&P 500   3,751.90 (-0.83%)
DOW   30,024.85 (-0.82%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
S&P 500   3,751.90 (-0.83%)
DOW   30,024.85 (-0.82%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
S&P 500   3,751.90 (-0.83%)
DOW   30,024.85 (-0.82%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
S&P 500   3,751.90 (-0.83%)
DOW   30,024.85 (-0.82%)
QQQ   280.06 (-0.68%)
AAPL   146.03 (-0.25%)
MSFT   247.12 (-0.83%)
META   136.92 (-1.48%)
GOOGL   101.06 (-0.36%)
AMZN   120.01 (-0.78%)
TSLA   236.23 (-1.90%)
NVDA   132.03 (-0.05%)
NIO   15.22 (-5.11%)
BABA   83.87 (-0.62%)
AMD   68.02 (+0.12%)
T   15.61 (-2.01%)
MU   53.44 (-2.36%)
CGC   2.99 (-2.61%)
F   12.35 (-1.28%)
GE   66.52 (-1.36%)
DIS   100.11 (-0.68%)
AMC   7.30 (-0.41%)
PYPL   94.32 (+0.52%)
PFE   43.50 (-1.41%)
NFLX   235.23 (-0.63%)
NASDAQ:TMCI

Treace Medical Concepts - TMCI Stock Forecast, Price & News

$22.96
+0.09 (+0.39%)
(As of 10/6/2022 10:18 AM ET)
Add
Compare
Today's Range
$22.94
$23.48
50-Day Range
$16.92
$24.18
52-Week Range
$12.48
$26.32
Volume
234 shs
Average Volume
474,783 shs
Market Capitalization
$1.27 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.50

Treace Medical Concepts MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
20.2% Upside
$27.50 Price Target
Short Interest
Bearish
7.57% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.56mentions of Treace Medical Concepts in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$4.97 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.82) to ($0.69) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.83 out of 5 stars

Medical Sector

874th out of 1,072 stocks

Surgical & Medical Instruments Industry

87th out of 103 stocks

TMCI stock logo

About Treace Medical Concepts (NASDAQ:TMCI) Stock

Treace Medical Concepts, Inc., an orthopedic medical device company, engages in the design, manufacture, and marketing of medical devices for foot and ankle surgeons in the United States. It offers Lapiplasty procedure that allows podiatric surgeons to treat all three dimensions of the bunion, providing patients with a cosmetic and medical improvement. The company also provides Lapiplasty Mini-Incision precision system. In addition, it offers products to address ancillary surgical procedures, including akin osteotomies, weil osteotomies, intercuneiform stabilization, lesser tarsometatarsal joint fusions, and autograft bone harvesting, as well as for MTP fusion. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra Beach, Florida.

Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

TMCI Stock News Headlines

5 Analysts Have This to Say About Treace Medical Concepts
Where Treace Medical Concepts Stands With Analysts
4 Analysts Have This to Say About Treace Medical Concepts
See More Headlines
Receive TMCI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Treace Medical Concepts and its competitors with MarketBeat's FREE daily newsletter.

TMCI Company Calendar

Last Earnings
8/09/2022
Today
10/06/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TMCI
Fax
N/A
Employees
248
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.50
High Stock Price Forecast
$32.00
Low Stock Price Forecast
$23.00
Forecasted Upside/Downside
+19.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-20,550,000.00
Pretax Margin
-34.46%

Debt

Sales & Book Value

Annual Sales
$94.42 million
Book Value
$1.75 per share

Miscellaneous

Free Float
32,195,000
Market Cap
$1.27 billion
Optionable
Not Optionable
Beta
-0.34

Key Executives

  • Mr. John T. TreaceMr. John T. Treace (Age 50)
    CEO, Founder & Director
    Comp: $688.14k
  • Mr. Thomas E. TimbieMr. Thomas E. Timbie (Age 64)
    Independent Director
    Comp: $39.12k
  • Mr. Mark L. Hair CPA (Age 52)
    Chief Financial Officer
    Comp: $688.22k
  • Mr. Aaron Berutti (Age 43)
    Sr. VP of Sales
    Comp: $323.62k
  • Mr. Terry W. Lubben (Age 57)
    Sr. VP of Operations
  • Mr. Jaime A. Frias (Age 60)
    Chief Legal Officer & Corp. Sec.
  • Mr. Scott Elder (Age 47)
    Sr. VP & Chief Compliance Officer
  • Dr. Sean F. Scanlan Ph.D. (Age 40)
    Sr. VP of Marketing
  • Mr. Daniel E. Owens (Age 50)
    Chief HR Officer
  • Ms. Shana Zink
    Sr. VP of Clinical Affairs, Medical Education & Reimbursement













TMCI Stock - Frequently Asked Questions

Should I buy or sell Treace Medical Concepts stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Treace Medical Concepts in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TMCI shares.
View TMCI analyst ratings
or view top-rated stocks.

What is Treace Medical Concepts' stock price forecast for 2022?

4 analysts have issued 12-month price objectives for Treace Medical Concepts' stock. Their TMCI share price forecasts range from $23.00 to $32.00. On average, they anticipate the company's share price to reach $27.50 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price.
View analysts price targets for TMCI
or view top-rated stocks among Wall Street analysts.

How have TMCI shares performed in 2022?

Treace Medical Concepts' stock was trading at $18.64 at the start of the year. Since then, TMCI stock has increased by 22.7% and is now trading at $22.87.
View the best growth stocks for 2022 here
.

When is Treace Medical Concepts' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our TMCI earnings forecast
.

How were Treace Medical Concepts' earnings last quarter?

Treace Medical Concepts, Inc. (NASDAQ:TMCI) released its quarterly earnings results on Tuesday, August, 9th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.02. The company earned $29.97 million during the quarter, compared to analyst estimates of $28.71 million. Treace Medical Concepts had a negative net margin of 34.46% and a negative trailing twelve-month return on equity of 39.92%.

What guidance has Treace Medical Concepts issued on next quarter's earnings?

Treace Medical Concepts updated its FY 2022 earnings guidance on Tuesday, September, 13th. The company provided EPS guidance of for the period. The company issued revenue guidance of $130.00 million-$134.00 million, compared to the consensus revenue estimate of $131.08 million.

When did Treace Medical Concepts IPO?

(TMCI) raised $150 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Morgan Stanley acted as the underwriters for the IPO and SVB Leerink and Stifel were co-managers.

What is Treace Medical Concepts' stock symbol?

Treace Medical Concepts trades on the NASDAQ under the ticker symbol "TMCI."

How do I buy shares of Treace Medical Concepts?

Shares of TMCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Treace Medical Concepts' stock price today?

One share of TMCI stock can currently be purchased for approximately $22.87.

How much money does Treace Medical Concepts make?

Treace Medical Concepts (NASDAQ:TMCI) has a market capitalization of $1.27 billion and generates $94.42 million in revenue each year. The company earns $-20,550,000.00 in net income (profit) each year or ($0.71) on an earnings per share basis.

How many employees does Treace Medical Concepts have?

The company employs 248 workers across the globe.

How can I contact Treace Medical Concepts?

Treace Medical Concepts' mailing address is 203 FORT WADE RD. SUITE 150, PONTE VEDRA FL, 32081. The official website for the company is www.treace.com. The company can be reached via phone at 904-373-5940 or via email at ir@treace.net.

This page (NASDAQ:TMCI) was last updated on 10/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.